Progress of PARP inhibitors in targeted therapy of small cell lung cancer
10.3760/cma.j.cn371439-20221123-00073
- VernacularTitle:PARP抑制剂在小细胞肺癌靶向治疗中的进展
- Author:
Li LIU
1
;
Siqi ZHU
;
Mengying SUN
;
Jingdong HE
Author Information
1. 南京医科大学附属淮安第一医院肿瘤内科，淮安 223300
- Keywords:
Small cell lung carcinoma;
Poly (ADP-ribose) polymerase inhibitors;
DNA repair;
Molecular targeted therapy;
Targeting preparation
- From:
Journal of International Oncology
2023;50(6):368-372
- CountryChina
- Language:Chinese
-
Abstract:
Small cell lung cancer (SCLC) is a rapidly developing malignant tumor, which is highly heterogeneous and prone to drug resistance, and the prognosis is usually poor. Poly ADP-ribose polymerase (PARP) inhibitors target the DNA damage response pathway, preventing DNA repair, thereby exerting anti-tumor effects. Currently, PARP inhibitors are used as monotherapy or in combination with DNA-damaging agents or immune checkpoint inhibitors in the treatment of SCLC. Although the current research results are limited, it can be seen that PARP inhibitors may be a breakthrough in the targeted therapy of SCLC.
